#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Polymyositis Congenital leptin deficiency Hodgkin's disease Progressive supranuclear palsy Antithrombin III deficiency Malignant neoplasm of choroid Obliterative bronchiolitis Tourette's disorder Mastocytosis Cutaneous T-cell lymphoma recurrent Oesophageal squamous cell carcinoma stage II Red blood cell abnormality Osteosarcoma recurrent Univentricular heart Glomerulonephritis acute More trials…

    Learn about Rare Diseases

    Proteus syndrome – Life with Disease Nodal marginal zone B-cell lymphoma Adrenocortical carcinoma – Treatment Glomerulonephritis rapidly progressive Leiomyosarcoma recurrent – Life with Disease Erdheim-Chester disease – Diagnostics Retinoblastoma – Trials in Disease Stevens-Johnson syndrome – Trials in Disease Extranodal marginal zone B-cell lymphoma (MALT type) – Treatment CADASIL – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dopamine Hydrochloride 68Ganota-Anti-Her2 Vhh1 ANOC-001 Epirubicin FERUMOXTRAN-10 Entinostat MAPLIRPACEPT Prasinezumab Amivantamab ZILEBESIRAN Levocetirizine Dihydrochloride PROMESTRIENE IHMA-2121771-1 Heparin Sodium Remdesivir Dl-Alpha-Tocopherol Bi 685509 ARTICAINE HYDROCHLORIDE Zanubrutinib BW-20805 More therapies…

    Learn about Your Condition

    Diabetic retinal oedema Systemic lupus erythematosus Post procedural complication Cutaneous lupus erythematosus Vulvovaginal pruritus Non-Hodgkin's lymphoma Neuropathy peripheral Cardiac sarcoidosis Oral neoplasm Transient ischaemic attack Hodgkin's disease Neoplasm malignant Burkitt's lymphoma Colon cancer Colon cancer stage III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Regional Du Cancer De Montpellier

Institut Regional Du Cancer De Montpellier

208 Avenue Des Apothicaires, Montpellier, 34298, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Cetuximab
    • Docetaxel
    • Methotrexate
    Belgium Czechia France Germany Greece Hungary +6

  • Study on Darolutamide and Capecitabine for Patients with Advanced Triple-Negative Androgen Receptor Positive Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Darolutamide
    • Capecitabine
    France

  • Study of Domvanalimab, Zimberelimab, and Chemotherapy for Patients with Advanced Esophageal or Gastric Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Oesophageal cancer metastatic
    • Oesophageal carcinoma
    • Gastric cancer
    Investigated Drugs:
    • Domvanalimab
    • Zimberelimab
    • Calcium Folinate
    France Greece Hungary Italy Lithuania Poland +3

  • Study of EGL-001 for Adults with Advanced or Metastatic Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Egl-001
    • Pembrolizumab
    France Spain

  • Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Capecitabine
    • Paclitaxel
    • Paclitaxel Albumin-Bound
    Austria Belgium Denmark France Germany Hungary +6

  • Study Comparing Avelumab, Cetuximab, and Radiotherapy with Standard Treatments for Patients with Advanced Head and Neck Squamous Cell Carcinoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Avelumab
    • Cetuximab
    • Cisplatin
    France

  • Study of Spartalizumab combined with FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, docetaxel) for patients with resectable gastric cancer before and after surgery

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastric cancer
    Investigated Drugs:
    • Spartalizumab
    • Folinic Acid
    • Docetaxel
    France

  • Study of NP137 with carboplatin, paclitaxel and pembrolizumab combination therapy for patients with advanced endometrial or cervical cancer who had prior chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Cervix carcinoma
    • Endometrial cancer
    Investigated Drugs:
    • Human Monoclonal Igg1 Antibody Against Netrin-1
    • Carboplatin
    • Paclitaxel
    France

  • Study on Chemotherapy and Hormone Therapy for Women Over 70 with ER-Positive, HER2-Negative Breast Cancer Using Cyclophosphamide and Drug Combination

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer female
    Investigated Drugs:
    • Cyclophosphamide
    • Docetaxel
    • Doxorubicin
    Belgium France

  • Study of OMX-0407 for Patients with Previously Treated Unresectable Solid Tumors

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Omx-0407
    Belgium France Spain
Previous Page
1 … 13 14 15 16 17 … 25
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!